Category - Announcements

Tempus Acquires Personalis and Raises the Stakes in the MRD Market

The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the...read more

Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues

Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of...read more

Abbott to acquire Exact Sciences

Invert launches Invert Assist, an AI-powered analysis interface built for bioprocess

ISAN FRANCISCO, CA, October 28, 2025 – Invert, a pioneer in AI-driven bioprocess software solutions, today announced the launch of Invert Assist, an AI-powered analysis interface for bioprocess that enables users to...read more

Stop Guessing. Start Diagnosing: The Marketing & Product-Market Fit Scorecard

BEVIMI Launches: A New Bid to Bring Pharma-Grade Rigor to Brain Health

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

Category - Announcements

Tempus Acquires Personalis and Raises the Stakes in the MRD Market

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues

Abbott to acquire Exact Sciences

Invert launches Invert Assist, an AI-powered analysis interface built for bioprocess

BEVIMI Launches: A New Bid to Bring Pharma-Grade Rigor to Brain Health

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

Tempus Announces the Acquisition of Paige

10x Genomics to Acquire Scale Biosciences

SCIMap: View Impact of Federal Health Research Cuts

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company’s multiomics strategy

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

Oracle, Cleveland Clinic, and G42 Announce Strategic Partnership to Launch AI-Based Global Healthcare Delivery Platform